The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Open accessAbstract
IMPORTANCE: The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective in patients with chronic lymphocytic leukemia (CLL). Reasons for discontinuing therapy with this drug and outcomes following discontinuation have not been evaluated outside of clinical trials with relatively short follow-up. OBJECTIVE: To determine features associated with discontinuation of ibrutinib therapy and outcomes. DESIGN, SETTING, AND PARTICIPANTS: A total of 308 patients participating in 4 sequential trials of ibrutinib at The Ohio State University Comprehensive Cancer Center were included. These clinical trials accrued patients included in this analysis from May 2010 until April 2014, and data were locked in June 2014. MAIN OUTCOMES AND MEASURES: Patients were evaluated for time to therapy discontinuation, reasons for discontinuation, and survival following discontinuation. For patients who discontinued therapy because of disease progression, targeted deep sequencing was performed in samples at baseline and time of relapse. RESULTS: With a median follow-up of 20 months, 232 patients remained on therapy, 31 had discontinued because of disease progression, and 45 had discontinued for other reasons. Disease progression includes Richter's transformation (RT) or progressive CLL. Richter's transformation appeared to occur early and CLL progressions later (cumulative incidence at 12 months, 4.5% [95% CI, 2.0%-7.0%] and 0.3% [95% CI, 0%-1.0%], respectively). Median survival following RT was 3.5 months (95% CI, 0.3-6.0 months) and 17.6 months (95% CI, 4.7 months-"not reached") following CLL progression. Sequencing on peripheral blood from 8 patients with RT revealed 2 with mutations in BTK, and a lymph node sample showed no mutations in BTK or PLCG2. Deep sequencing on 11 patients with CLL progression revealed BTK or PLCG2 mutations in all. These mutations were not identified before treatment in any patient. CONCLUSIONS AND RELEVANCE: This single-institution experience with ibrutinib confirms it to be an effective therapy and identifies, for the first time, baseline factors associated with ibrutinib therapy discontinuation. Outcomes data show poor prognosis after discontinuation, especially for those patients with RT. Finally, sequencing data confirm initial reports associating mutations in BTK and PLCG2 with progression and clearly show that CLL progressions are associated with these mutations, while RT is likely not. TRIAL REGISTRATIONS: clinicaltrials.gov Identifiers:NCT01105247, NCT01217749, NCT01589302, and NCT01578707.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In published studies of disease progression during BTKi therapy,approximately 35% of patients were found to have aBTK mutation alone, an additional 10% had a coexisting mutations in PLCG2, 5% of cases had a PLCG2mutation alone, and the remaining 50% were wild-type (WT) for BTK and PLCG2 (Figure 2)(12, 19, 21–31).”
From Resistance Mechanisms and Approach to Chronic Lymphocytic Leukemia after BTK Inhibitor Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Interestingly, two separate studies observed that there were no PLCγ2 or BTK mutations detected in patients with CLL before Ibrutinib treatment (127, 128).”
From The role of PLCγ2 in immunological disorders, cancer, and neurodegeneration (2021) · cites this paper as [128]
In the citing paper
“While the most common ibrutinib-resistant BTK mutant is C481S, other mutants observed in patients include C481R, C481F, C481Y, T474I, and T474S.33”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,957
Clinical staging of chronic lymphocytic leukemia
Rai, K., Sawitsky, A., Ep, C., Chanana, A. D., Levy, R., & Pasternack, B. (1975) · Blood · doi:10.1182/blood.v46.2.219.219 · Cited by 2,789
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Self-citationIdelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,725
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S. M., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S. E., Tam, C. S. L., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,665
Self-citationResistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275
Self-citationDubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., et al. (2013) · Blood · doi:10.1182/blood-2013-06-507947 · Cited by 810
Self-citationHerman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Self-citationPonader, S., Chen, S.-S., Buggy, J. J., Balakrishnan, K., Gandhi, V., Wierda, W. G., Keating, M. J., O'Brien, S., Chiorazzi, N., & Burger, J. A. (2012) · Blood · doi:10.1182/blood-2011-10-386417 · Cited by 640
Cited by
Sorted by citations
Items 301–400 of 585
BCR inhibitor failure in CLL: an unmet need
Jain, N., & O'Brien, S. M. (2016) · Blood · doi:10.1182/blood-2016-09-739664 · Cited by 16
Pozzo, F., Forestieri, G., Vit, F., Ianna, G., Tissino, E., Bittolo, T., Papotti, R., Gaglio, A., di Bergamo, L. T., Steffan, A., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02301-y · Cited by 16
Hampel, P. J., Rabe, K. G., Wang, Y., Hwang, S. R., Kenderian, S. S., Muchtar, E., Leis, J. F., Koehler, A. B., Tsang, M., Hilal, T., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02492-4 · Cited by 16
Bennett, C. L., Berger, J. R., Sartor, O. A., Carson, K. R., Hrushesky, W. J. M., Georgantopoulos, P., Raisch, D. W., Norris, L. B., & Armitage, J. O. (2016) · British Journal of Haematology · doi:10.1111/bjh.14322 · Cited by 16
Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease
Tees, M. T., & Flinn, I. W. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2017.1270203 · Cited by 16
Recent therapeutic advances in chronic lymphocytic leukemia
Bose, P., & Gandhi, V. V. (2017) · F1000Research · doi:10.12688/f1000research.11618.1 · Cited by 16
Strategies to Overcome Resistance Mutations of Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Liu, L., Shi, B., Wang, X., & Xiang, H. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0145 · Cited by 18
Zinzani, P. L., Rambaldi, A., Gaïdano, G., Girmenia, C., Marchetti, M., Pane, F., Tura, S., & Barosi, G. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.04.016 · Cited by 16
Li, J., Huang, Y. Q., Zhang, Y., Wen, J., Chen, Y., Wang, L., Jiang, P., & Hu, J. (2021) · Medical Oncology · doi:10.1007/s12032-021-01470-5 · Cited by 16
Iskierka‐Jazdzewska, E., Puła, B., Szeremet, A., Hus, M., Gołoś, A., Hołojda, J., Piszczek, W., Steckiewicz, P., Wojciechowska, M., Zaucha, J. M., et al. (2019) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/99911 · Cited by 16
Michallet, A., Campidelli, A., Lequeu, H., Dilhuydy, M., Tournilhac, O., Fornecker, L., Dupuis, J., Cymbalista, F., de Guibert, S., Delmer, A. J., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24715 · Cited by 16
Integrin Signaling Shaping BTK-Inhibitor Resistance
Polcik, L., Dannewitz Prosseda, S., Pozzo, F., Zucchetto, A., Gattei, V., & Hartmann, T. N. (2022) · Cells · doi:10.3390/cells11142235 · Cited by 15
Hematopoietic Cell Transplantation for Richter Syndrome
El‐Asmar, J., & Kharfan‐Dabaja, M. A. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.06.025 · Cited by 15
Smith, C. I. E. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.11.008 · Cited by 15
Innocenti, I., Rossi, D., Trapè, G., Autore, F., Larocca, L. M., Gomes, V., Cerri, M., Falcucci, P., Sica, S., Gaïdano, G., et al. (2018) · Hematological Oncology · doi:10.1002/hon.2502 · Cited by 15
Cramer, P., von Tresckow, J., Robrecht, S., Bahlo, J., Fürstenau, M., Langerbeins, P., Pflug, N., Al‐Sawaf, O., Heinz, W., Vehling‐Kaiser, U., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.223693 · Cited by 15
Lama, T. G., Kyung, D., & O'Brien, S. M. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1797482 · Cited by 15
Arrhythmia Patterns in Patients on Ibrutinib
Fazal, M., Kapoor, R., Cheng, P. P., Rogers, A. J., Narayan, S. M., Wang, P. J., Witteles, R. M., Perino, A. C., Baykaner, T., & Rhee, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.792310 · Cited by 15
Sinha, S., Boysen, J. C., Rabe, K. G., Kabat, B., Slager, S. L., Parikh, S. A., Secreto, C. R., Call, T. G., Shanafelt, T. D., Leis, J. F., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26444 · Cited by 15
Acquired Mutations in Patients with Relapsed/Refractory Cll Who Progressed in the Alpine Study
Brown, J. R., Li, J., Eichhorst, B. F., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Huang, R., Shi, Y., Idoine, A., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024014206 · Cited by 14
Gu, D., Li, J., & Miao, Y. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2144218 · Cited by 14
Prognostication in chronic lymphocytic leukemia
Moia, R., & Gaïdano, G. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.02.002 · Cited by 14
Bravo-González, A., Alasfour, M., Soong, D., Noy, J., & Pongas, G. N. (2024) · Cancers · doi:10.3390/cancers16203434 · Cited by 14
Chronic lymphocytic leukemia therapy: new targeted therapies on the way
Vitale, C., & Burger, J. A. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1168401 · Cited by 14
Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors
Musumeci, F., Sanna, M., Greco, C., Giacchello, I., Fallacara, A. L., Amato, R., & Schenone, S. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1355908 · Cited by 14
Relapsed CLL: sequencing, combinations, and novel agents
Brown, J. R. (2018) · Hematology · doi:10.1182/asheducation-2018.1.248 · Cited by 14
Veal, G. J., Amankwatia, E. B., Paludetto, M., Möcklinghoff, T., THOMSON, F. J., André, N., Ciccolini, J., & Chatelut, É. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000606 · Cited by 14
Chan, K. L., Blombery, P. A., Jones, K. L., Lade, S., Carney, D. A., Tran, H., Seymour, J. F., & Tam, C. S. L. (2016) · British Journal of Haematology · doi:10.1111/bjh.14062 · Cited by 14
Molica, S., Gianfelici, V., & Levato, L. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1724282 · Cited by 13
Hillmen, P., Xie, J., Yong, A., Waweru, C., Sorof, T. A., Goyal, R., & Davis, K. L. (2021) · eJHaem · doi:10.1002/jha2.174 · Cited by 13
Huang, Q., Borra, S., Li, J., Wang, L., Shrestha, S., Sundaram, M., & Janjan, N. A. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.20095 · Cited by 13
Cramer, P., Tausch, E., von Tresckow, J., Giza, A., Robrecht, S., Schneider, C., Fürstenau, M., Langerbeins, P., Al‐Sawaf, O., Pelzer, B. W., et al. (2021) · Blood · doi:10.1182/blood.2020010484 · Cited by 13
Yano, M., Sharpe, C., Lance, J. R., Ravikrishnan, J., Zapolnik, K., Mo, X., Woyach, J. A., Sampath, D., Kittai, A. S., Vasu, S., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021005883 · Cited by 14
Self-citationMunakata, W., Ando, K., Yokoyama, M., Fukuhara, N., Yamamoto, K., Fukuhara, S., Ohmachi, K., Mishima, Y. M., Ichikawa, S., Ogiya, D., et al. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03514-6 · Cited by 13
Idelalisib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Barrientos, J. C. (2016) · Future Oncology · doi:10.2217/fon-2016-0003 · Cited by 13
Jarošová, M., Plevová, K., Kotašková, J., Doubek, M., & Pospı́šilová, Š. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1576038 · Cited by 13
Shadman, M. S., Maloney, D. G., Storer, B. E., Sandmaier, B. M., Chauncey, T. R., Andersen, N. S., Niederwieser, D. W., Shizuru, J. A., Bruno, B., Pulsipher, M. A., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0660-8 · Cited by 13
Pasqua, L. G. D., Abdallah, M. M., Feletti, F., Vairetti, M., & Ferrigno, A. (2024) · Pharmaceuticals · doi:10.3390/ph17040484 · Cited by 13
PET/Computed Tomography in Chronic Lymphocytic Leukemia and Richter Transformation
Rhodes, J. M., & Mato, A. R. (2019) · PET Clinics · doi:10.1016/j.cpet.2019.03.007 · Cited by 12
Mateu‐Albero, T., Juárez-Sánchez, R., Loscertales, J., Mol, W., Terrón, F., Muñoz‐Calleja, C., & Cuesta‐Mateos, C. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03014-2 · Cited by 13
BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib
Jackson, R. A., Britton, R. G., Jayne, S., Lehmann, S., Cowley, C. M., Trethewey, C. S., Smith, V. M., Schmid, R., Fegan, C., Walter, H. S., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009366 · Cited by 12
Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies
Rafei, H., & Kharfan‐Dabaja, M. A. (2017) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2017.04.002 · Cited by 12
Using prognostic models in CLL to personalize approach to clinical care: Are we there yet?
Mina, A. A., Sandoval-Sus, J. D., Sleiman, E., Pinilla-Ibarz, J. A., Awan, F. T., & Kharfan‐Dabaja, M. A. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.10.003 · Cited by 12
Self-citationManagement of relapsed/refractory Chronic Lymphocytic Leukemia
Woyach, J. A. (2022) · American Journal of Hematology · doi:10.1002/ajh.26683 · Cited by 12
Self-citationJamroziak, K., Szymczyk, A., Hus, M., Wojciechowska, M., Knopińska‐Posłuszny, W., Hołojda, J., Hałaburda, K., Warzocha, K., & Iskierka‐Jazdzewska, E. (2017) · European Journal Of Haematology · doi:10.1111/ejh.13016 · Cited by 12
Huntington, S. F., Nigris, E. D., Puckett, J. T., Kamal‐Bahl, S. J., Farooqui, M. Z. H., Ryland, K. E., Sarpong, E., Leng, S., Yang, X., & Doshi, J. A. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2256911 · Cited by 11
Chemoimmunotherapy Is Not Dead Yet in Chronic Lymphocytic Leukemia
Brown, J. R., & Kay, N. E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6810 · Cited by 11
Mauro, F. R., Caputo, M. D., Rosati, S., Pepe, S., Benedittis, D. D., Luca, M. L. D., & Foà, R. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1495557 · Cited by 11
An update on: molecular genetics of high-risk chronic lymphocytic leukemia
Moia, R., Patriarca, A., Deambrogi, C., Rasi, S., Favini, C., Kodipad, A. A., Schipani, M., & Gaïdano, G. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2020.1697225 · Cited by 11
Approaches for relapsed CLL after chemotherapy-free frontline regimens
Roeker, L. E., & Mato, A. R. (2020) · Hematology · doi:10.1182/hematology.2020000168 · Cited by 12
Black, G. S., Huang, X., Qiao, Y., Tarapcsák, S., Rogers, K. A., Misra, S., Byrd, J. C., Marth, G., Stephens, D. M., & Woyach, J. A. (2022) · Blood · doi:10.1182/blood.2021015132 · Cited by 11
Self-citationMartino, E. A., Mauro, F. R., Reda, G., Laurenti, L., Visentin, A., Frustaci, A. M., Vigna, E., Pepe, S., Catania, G., Loseto, G., et al. (2024) · Hematological Oncology · doi:10.1002/hon.3249 · Cited by 11
Hampel, P. J., Call, T. G., Ding, W., Muchtar, E., Kenderian, S. S., Wang, Y., Leis, J. F., Witzig, T. E., Koehler, A. B., Fonder, A. L., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25690 · Cited by 11
Apoptotic resistance in chronic lymphocytic leukemia and therapeutic perspectives
Bagacean, C., Tomuleasa, C., Tempescul, A., Grewal, R., Brooks, W. H., Berthou, C., & Renaudineau, Y. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1600468 · Cited by 11
Huber, H., Edenhofer, S., Estenfelder, S., & Stilgenbauer, S. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s102646 · Cited by 10
Thompson, M. C., & Mato, A. R. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.03.008 · Cited by 10
The molecular map of CLL and Richter's syndrome
Sud, A., Parry, E. M., & Wu, C. J. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.01.009 · Cited by 10
Dong, N. C., Lopes-Garcia, L. R., Viñal, D., Bachmeier, C. A., Shah, B. D., Nishihori, T., Khimani, F., Davila, M. L., Lazaryan, A., Pinilla-Ibarz, J. A., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.02.021 · Cited by 10
Ogunleye, F. N., Glick, A., Stender, M., & Jaiyesimi, I. A. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.11.011 · Cited by 10
Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma
Rosenthal, A. C. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0383-0 · Cited by 10
Transformation of chronic lymphocytic leukemia into B-cell acute lymphoblastic leukemia
Yun, S., Zhang, L., Patel, M. R., Knepper, T. C., Chávez, J. C., & Pinilla-Ibarz, J. A. (2018) · Blood · doi:10.1182/blood-2017-11-819276 · Cited by 10
Ibrutinib-related atrial fibrillation: Therapeutic challenges
Kapelios, C. J., Bonou, M. S., Diamantopoulos, P. T., Angelopoulou, M. K., Masoura, C., Barbetseas, J. D., & Viniou, N. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218785983 · Cited by 10
Richter's Transformation in the Era of Kinase Inhibitor Therapy: A Review
Ayers, E. C., & Mato, A. R. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.08.021 · Cited by 10
Levin, M., Kater, A. P., Mattsson, M., Kersting, S., Ranti, J., Tran, H. T. T., Nasserinejad, K., & Niemann, C. U. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-039168 · Cited by 10
Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib
Dostálová, H., & Kryštof, V. (2024) · Hematological Oncology · doi:10.1002/hon.3294 · Cited by 9
Σταματόπουλος, Κ., Pavlová, Š., Al‐Sawaf, O., Chatzikonstantinou, T., Karamanidou, C., Gaïdano, G., Cymbalista, F., Kater, A. P., Rawstron, A. C., Scarfò, L., et al. (2024) · HemaSphere · doi:10.1002/hem3.113 · Cited by 9
Pepe, S., Vitale, C., Giannarelli, D., Visentin, A., Sanna, A., Frustaci, A. M., Olivieri, J., Quaglia, F. M., Gozzetti, A., Sportoletti, P., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02666-8 · Cited by 10
Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Varma, G., Johnson, T. P., & Advani, R. H. (2016) · PubMed · Cited by 9
The safety of Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia
Tran, P. N., & O'Brien, S. M. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1344213 · Cited by 9
Chiodin, G., Drennan, S., Martino, E. A., Ondrišová, L., Henderson, I., Rio, L. D., Tracy, I., D’Avola, A., Parker, H., Bonfiglio, S., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006659 · Cited by 9
Hatashima, A., Karami, M., & Shadman, M. S. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2113384 · Cited by 9
Catapano, R., Sepe, L., Toscano, E., Paolella, G., Chiurazzi, F., Barbato, S., Bruzzese, D., Arianna, R., Grosso, M., Romano, S., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1010984 · Cited by 9
Moldovianu, A.-M., Stoia, R. A., Vasilică, M., Ursuleac, I., BADELITA, S. N., Tomescu, A. A., Preda, O. D., Bardaş, A., Cirstea, M., & Coriu, D. (2023) · Medicina · doi:10.3390/medicina59020324 · Cited by 9
Woolston, D. W., Lee, N. D., Shadman, M. S., Latorre-Esteves, E. S., Tee, X. R., Fredrickson, J., Kohrn, B. F., Ujjani, C. S., Eckel, A. M., Till, B. G., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.283372 · Cited by 9
Baucher, L., Lemiale, V., Joseph, A., Wallet, F., de Chambrun, M. P., Ferré, A., Lombardi, R., Platon, L., Contejean, A., Fuseau, C., et al. (2023) · Annals of Intensive Care · doi:10.1186/s13613-023-01219-5 · Cited by 9
Richter's transformation: Transforming the clinical landscape
Barrett, A., Appleby, N., Dreau, H. M.-P., Fox, C. P., Munir, T., & Eyre, T. A. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101163 · Cited by 9
Promises and pitfalls of targeted agents in chronic lymphocytic leukemia
Lew, T. E., Anderson, M. A., & Seymour, J. F. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2019.108 · Cited by 9
Park, H. S., Oh, A., Keum, C., Lee, J., Lee, J. K., Son, B. R., Shin, K. S., & Hahn, Y. (2021) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2021.104387 · Cited by 9
Magic pills: new oral drugs to treat chronic lymphocytic leukemia
Vitale, C., Griggio, V., Todaro, M., Salvetti, C., Boccadoro, M., & Coscia, M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1293655 · Cited by 9
Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia
Arruga, F., & Deaglio, S. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_12 · Cited by 9
Darragh, A. C., Hanna, A. M., Lipner, J., King, A. J., Servant, N. B., & Jahic, M. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00540 · Cited by 8
Comparative arrhythmia patterns among patients on tyrosine kinase inhibitors
Chen, W., Fazal, M., Loh, A., Kapoor, R., Gomez, S. E., Shah, S., Rogers, A. J., Narayan, S. M., Wang, P. J., Witteles, R. M., et al. (2023) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-023-01575-z · Cited by 8
Xie, J., Jang, A., Vegel, A. J., Hajja, Y., Mouawad, Y., Baghian, A., Berbari, B., Schmid, J. L., Socola, F. A., Safah, H. F., et al. (2021) · Leukemia Research Reports · doi:10.1016/j.lrr.2021.100247 · Cited by 8
Gángó, A., Kiss, R., Farkas, P., Hanna, E., Demeter, J., Deák, B., Lévai, D., Kotmayer, L., Alpár, D., Matolcsy, A., et al. (2021) · Pathology · doi:10.1016/j.pathol.2021.04.008 · Cited by 8
Mauro, F. R., Paoloni, F. P., Molica, S., Reda, G., Trentin, L., Sportoletti, P., Marchetti, M., Pietrasanta, D., Marasca, R., Gaïdano, G., et al. (2021) · Cancers · doi:10.3390/cancers14010207 · Cited by 8
Marini, B. L., Samanas, L., & Perissinotti, A. J. (2016) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155216656929 · Cited by 8
Targeted Therapy in Chronic Lymphocytic Leukemia (CLL)
Pettijohn, E. M., & Ma, S. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0358-1 · Cited by 8
Venetoclax for the treatment of patients with chronic lymphocytic leukemia
Crombie, J. L., & Davids, M. S. (2017) · Future Oncology · doi:10.2217/fon-2017-0031 · Cited by 8
Ghia, P., Długosz‐Danecka, M., Scarfò, L., & Jurczak, W. J. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1864352 · Cited by 8
Albi, E., Capasso, A., Schiattone, L., Ghia, P., & Scarfò, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.01.009 · Cited by 9
Joseph, R. E., Wales, T. E., Jayne, S., Britton, R. G., Fulton, D. B., Engen, J. R., Dyer, M. J. S., & Andreotti, A. H. (2024) · eLife · doi:10.7554/elife.95488 · Cited by 8
Buchrits, S., Trieman, G., Giladi, O., Hofstetter, L., Gurion, R., Granot, G., Shacham‐Abulafia, A., Raanani, P., & Gafter‐Gvili, A. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06502-y · Cited by 8
Rule, S. A., & Chen, R. W. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1506327 · Cited by 7
Dissecting CLL through high-dimensional single-cell technologies
Gohil, S. H., & Wu, C. J. (2019) · Blood · doi:10.1182/blood-2018-09-835389 · Cited by 8
Cellular Therapy in High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter Syndrome
Barbanti, M. C., Appleby, N., Kesavan, M., & Eyre, T. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.888109 · Cited by 7
Frustaci, A. M., Poeta, G. D., Visentin, A., Sportoletti, P., Fresa, A., Vitale, C., Murru, R., Chiarenza, A., Sanna, A., Mauro, F. R., et al. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221127550 · Cited by 7
Richter Transformation of Chronic Lymphocytic Leukemia—Are We Making Progress?
Audil, H. Y., Kosydar, S., Larson, D. P., & Parikh, S. A. (2023) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-023-00701-y · Cited by 7
Yan, Y., Lv, R., Wang, T., Yu, Y., Huang, Y., Xiong, W., Li, Y., Sui, W., Wang, Q., Huang, W., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1184395 · Cited by 7
Combined analysis of the impact of second-generation BTK inhibitors on patient outcomes
Redd, R. A., Ford, J. G., Lei, M. M., Abramson, J. S., & Soumerai, J. D. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2254876 · Cited by 7
PET/CT in leukemia: utility and future directions
Al‐Ibraheem, A., Allouzi, S., Abdlkadir, A. S., Mikhail-Lette, M., Al-Rabi, K. H., Ma’koseh, M., Knoll, P., Abdelrhman, Z., Shahin, O. A., Juweid, M. E., et al. (2024) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001846 · Cited by 7
Metadata
- Authors
- Maddocks, K. J., Ruppert, A. S., Lozanski, G., Heerema, N. A., Zhao, W., Abruzzo, L., Lozanski, A., Davis, M., Gordon, A., Smith, L. L., Mantel, R., Jones, J. A., Flynn, J. M., Jaglowski, S. M., Andritsos, L. A., Awan, F., Blum, K. A., Grever, M. R., Johnson, A. J., Byrd, J. C., & Woyach, J. A.
- Affiliations
- The Ohio State University (US)
- Corresponding author
- Woyach, Jennifer A.
- ORCID
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2015-04-01
- Volume
- 1
- Issue
- 1
- Pages
- 80
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC4520535
- OpenAlex
- W1999128869
- Cited by
- 584
- References
- 21
- Citations by year
- 2026: 13 · 2025: 29 · 2024: 35 · 2023: 38 · 2022: 47 · 2021: 59 · 2020: 65 · 2019: 72 · 2018: 60 · 2017: 85 · 2016: 64 · 2015: 16
- FWCI
- 41.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (4p01ca081534-16)
- National Cancer Institute (P01CA095426, U10CA180861, P50CA140158, R01CA183444, P01CA95426, K23CA178183, R01CA177292, P01-CA-081534)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- chronic lymphocytic leukemia, BTK inhibitors, treatment discontinuation, Richter transformation, BTK mutations, PLCG2 mutations, relapse, deep sequencing, prognostic factors, sequential clinical trials, targeted therapy resistance
- MeSH terms
- Agammaglobulinaemia Tyrosine Kinase, Adenine, Adult, Aged, Aged, 80 and over, Clinical Trials as Topic, DNA Mutational Analysis, Female, Humans, Male, Middle Aged, Mutation, Ohio, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Recurrence, Risk Factors, Time Factors, Biomarkers, Tumor, Leukemia, Lymphocytic, Chronic, B-Cell, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Phospholipase C gamma, Kaplan-Meier Estimate, Molecular Targeted Therapy, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
